Smith & Nephew SNATS (NYSE:SNN) Raised to Buy at Wall Street Zen

Smith & Nephew SNATS (NYSE:SNN – Get Free Report) was upgraded by Wall Street Zen from a “hold” rating to a “buy” rating in a report released on Sunday, Wall Street Zen reports.

A number of other research firms have also recently commented on SNN. BTIG Research began coverage on shares of Smith & Nephew SNATS in a research note on Monday, August 31st. They set a “neutral” rating for the company. Bank of America downgraded shares of Smith & Nephew SNATS from a “buy” rating to a “neutral” rating in a research report on Tuesday, September 8th. Zacks Research lowered shares of Smith & Nephew SNATS from a “hold” rating to a “strong sell” rating in a research note on Thursday, November 5th. Morgan Stanley lowered shares of Smith & Nephew SNATS from an “overweight” rating to an “equal weight” rating in a research note on Wednesday, September 2nd. Finally, Berenberg Bank set a $33.88 price objective on Smith & Nephew SNATS in a report on Friday, September 11th. One equities research analyst has rated the stock with a Buy rating, eight have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, Smith & Nephew SNATS has an average rating of “Reduce” and a consensus target price of $31.91.

Read Our Latest Analysis on SNN

Smith & Nephew SNATS Stock Down 0.9%

SNN opened at $30.99 on Friday. The company has a quick ratio of 1.11, a current ratio of 2.14 and a debt-to-equity ratio of 0.62. Smith & Nephew SNATS has a 52-week low of $26.12 and a 52-week high of $37.09. The firm’s fifty day simple moving average is $28.77 and its two-hundred day simple moving average is $30.97.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. boosted its stake in Smith & Nephew SNATS by 37.0% during the 3rd quarter. Goldman Sachs Group Inc. now owns 4,204,122 shares of the medical equipment provider’s stock worth $113,343,000 after purchasing an additional 1,134,524 shares during the last quarter. Lighthouse Investment Partners LLC purchased a new stake in shares of Smith & Nephew SNATS during the third quarter worth $752,000. Cetera Investment Advisers grew its holdings in shares of Smith & Nephew SNATS by 7.4% during the third quarter. Cetera Investment Advisers now owns 35,764 shares of the medical equipment provider’s stock worth $964,000 after buying an additional 2,459 shares in the last quarter. FORA Capital LLC acquired a new stake in shares of Smith & Nephew SNATS in the third quarter valued at about $353,000. Finally, Bleakley Financial Group LLC raised its position in shares of Smith & Nephew SNATS by 5.6% in the third quarter. Bleakley Financial Group LLC now owns 37,576 shares of the medical equipment provider’s stock valued at $1,013,000 after buying an additional 1,997 shares during the last quarter. Hedge funds and other institutional investors own 25.64% of the company’s stock.

About Smith & Nephew SNATS

(Get Free Report)

Smith & Nephew plc is a global medical technology company that develops and sells products used in surgery, orthopaedics and wound care. Its offerings include implants for hip and knee replacement, instruments and devices for sports medicine and ear, nose and throat procedures, and products designed to manage wounds and support tissue repair. Founded in 1856 in Hull, England, the company began as a pharmacy business before expanding into medical products. It now serves healthcare providers and patients in markets around the world.

See Also

Analyst Recommendations for Smith & Nephew SNATS (NYSE:SNN)

Receive News & Ratings for Smith & Nephew SNATS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew SNATS and related companies with MarketBeat.com's FREE daily email newsletter.